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 44 
ABSTRACT 45 
 46 
Objective. Gut microbial products are involved in type 2 diabetes, obesity and insulin 47 
resistance. In particular, hippurate, a hepatic phase 2 conjugation product of microbial 48 
benzoate metabolism, has been associated with a healthy phenotype. This study aims to 49 
identify metagenomic determinants and test protective effects of hippurate. 50 
 51 
Design. We profiled the urine metabolome by 1H Nuclear Magnetic Resonance (NMR) 52 
spectroscopy to derive associations with metagenomic sequences in 271 middle-aged 53 
Danish individuals to identify dietary patterns in which urine hippurate levels were associated 54 
with health benefits. We follow up with benzoate and hippurate infusion in mice to 55 
demonstrate causality on clinical phenotypes.  56 
 57 
Results. In-depth analysis identifies that the urine hippurate concentration is associated with 58 
microbial gene richness, microbial functional redundancy as well as functional modules for 59 
microbial benzoate biosynthetic pathways across several enterotypes. Through dietary 60 
stratification, we identify a subset of study participants consuming a diet rich in saturated fat 61 
in which urine hippurate, independently of gene richness, accounts for links with metabolic 62 
health that we previously associated with gene richness. We then demonstrate causality in 63 
vivo through chronic subcutaneous infusions of hippurate or benzoate (20 nmol/day) 64 
resulting in improved glycemic control in mice fed a high-fat diet. Hippurate improved insulin 65 
secretion through increased β-cell mass and reduced liver inflammation and fibrosis, 66 
whereas benzoate treatment resulted in liver inflammation.  67 
 68 
Conclusion. Our translational study shows that the benzoate-hippurate pathway brings a 69 
range of metabolic improvements in the context of high-fat diets, highlighting the potential of 70 
hippurate as a mediator of metabolic health. 71 
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 73 
 74 
INTRODUCTION 75 
 76 
The human obesity epidemic raises the risk of type 2 diabetes and cardiovascular disease. 77 
Dysbiosis of the gut microbiome is now recognised as a key feature of these disorders.[1] 78 
The microbiome collectively encodes up to 10 million different microbial genes.[2,3] In 79 
particular, gene richness has been proposed as a marker of ecological diversity mirroring 80 
improvements in metabolic health.[4,5] Although the microbiome directly impacts various 81 
biological processes of the host through production or degradation of a multitude of 82 
compounds, the vast majority of molecules involved in this chemical crosstalk remains 83 
elusive.[6-9] 84 
There is growing evidence that hippurate, one of the most abundant microbial-host co-85 
metabolites in human urine, is positively associated with metabolic health through inverse 86 
associations with blood pressure, fatty liver disease, visceral fat mass and Crohn’s 87 
disease.[10-14] Its microbial precursor, benzoate is taken up by organic anion transporter 88 
MCT2[15] and conjugated with glycine in the liver and kidney to form hippurate. We showed 89 
in a genetic cross between diabetic and normoglycemic rat strains that serum benzoate 90 
under host genome control.[16] Hippurate was recently shown to be associated both with 91 
microbiota diversity based on 16S rRNA gene sequencing[17] and with reduced risk of 92 
metabolic syndrome.[13] 93 
However, there is a critical need for an in-depth characterization of the complex nutrition-94 
microbiome-host interaction in the benzoate-hippurate pathway, in relation to: i) associations 95 
with enterotype, gene richness and functional redundancy, ii) population stratification 96 
according to nutritional patterns to identify patient sub-groups in which hippurate improves 97 
metabolic health, and iii) translational elucidation of these effects on host phenotypes in vivo. 98 
To address these specific points, we characterized the urinary metabolome and the fecal 99 
microbiome of 271 middle-aged non-diabetic Danish individuals from the MetaHIT study.[4] 100 
Through dietary stratification we delineate the complex interaction between dietary intake, 101 
microbiome and metabolome its impact on body weight, immune and metabolic markers, 102 
which we further confirm and characterise in a mouse model of diet-induced obesity and 103 
diabetes. 104 
  105 
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
perpetuity.
this preprint (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in 
The copyright holder for. http://dx.doi.org/10.1101/2019.12.15.876672doi: bioRxiv preprint first posted online Dec. 16, 2019; 
 5 
METHODS 106 
 107 
Human subjects 108 
All analyses were done on non-diabetic Danish individuals from the MetaHIT study 109 
(n=271),[4,18] including the subset of 193 individuals who completed a validated food 110 
frequency questionnaire (FFQ).[19] The study was approved by the Ethical Committees of 111 
the Capital Region of Denmark (HC-2008-017 and H-15000306) and was in accordance with 112 
the principles of the Declaration of Helsinki. All individuals gave written informed consent 113 
before participating in the study. Sampling and clinical phenotyping were performed as 114 
described previously.[4,18] In short, all study participants were recruited from the population-115 
based Inter99 study.[20]. The study program consisted of two visits with approximately 14 116 
days apart. At the first visit all participants were examined in the morning after an overnight 117 
fast. Blood sampling was performed at the fasting state, and urine was collected upon arrival 118 
at the centre. At the second visit, a Dual Energy X-Ray Absorptiometry (DXA) scan was 119 
performed. Serum glycine levels were previously assessed.[19] Estimated glomerular 120 
filtration rate (eGFR) was calculated with the CKD-EPI formula with age, gender and 121 
creatinine (μmol/L) and without ethnicity factor.[21] 122 
Dietary assessment 123 
A subset of the study participants (n=193) completed a validated FFQ in order to obtain 124 
information on their habitual dietary habits.[22] The FFQ gathered dietary information from 125 
all meals during a day and the intake frequencies within the past months were recorded. The 126 
dietary data were evaluated by determining the consumed quantity and multiplying the 127 
portion size by the corresponding consumption frequency as reported in the FFQ. Standard 128 
portion sizes for women and men, separately, were used in this calculation; all food items in 129 
the FFQ were linked to food items in the Danish Food Composition Databank as previously 130 
described.[19]. Estimation of daily intake of macro-and micronutrients for each participant 131 
was based on calculations in the software program FoodCalc version1.3 132 
(http://www.ibt.ku.dk/jesper/FoodCalc/Default.htm). 133 
Sample collection 134 
Fecal sample collection and analysys was performed as previously described.[4] Urine was 135 
collected at the first visit upon arrival at the study site and stored at -80°C until analysis. 136 
Metabolic profiling 137 
Urine samples were randomized, prepared and measured on a NMR spectrometer (Bruker) 138 
operating at 600.22 MHz 1H frequency using previously published experimental 139 
parameters[23] The 1H NMR spectra were then pre-processed and analyzed as previously 140 
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reported[10] using Statistical Recoupling of Variables-algorithm.[24] Structural assignment 141 
was performed as reviewed in [25], using in-house and publicly available databases. 142 
Metagenomics 143 
Shotgun sequencing of microbial DNA and metagenomics processing workflow for gene 144 
richness was performed as previously published.[4] Sequences were mapped onto the 145 
previously released integrated gene catalog.[2] Following the previously published 146 
strategy,[26] we built a novel set of manually curated gut-specific metabolic modules 147 
(GMMs) to describe and map microbial phenylpropanoid metabolism from shotgun 148 
metagenomic data. The set of 20 modules, following KEGG syntax, is provided in 149 
supplement, including references to the original publications where pathways were 150 
discovered and described (Supplementary List). 151 
Univariate statistical analysis 152 
A ROUT test was performed to identify potential outliers (Q=1%). For statistical comparisons 153 
between study groups, normality was tested using D'Agostino-Pearson omnibus normality 154 
test, then one-way ANOVA was used, followed by Tukey’s HSD post hoc testing when data 155 
were normally distributed, otherwise groups were compared using the two-tailed Mann-156 
Whitney test. Data are displayed as mean ± s.e.m in all figures. Multiple testing corrections 157 
were performed using Storey’s procedure.[27] 158 
Multivariate statistics 159 
Probabilistic principal component analysis (PCA) was performed using MATLAB R2014a 160 
function ‘ppca’ to handle missing values. Unconstrained ordination was performed using 161 
principal coordinates analysis (PCoA) to visualize inter-individual variation in microbiota 162 
composition using Bray-Curtis dissimilarity on the genus-level abundance matrix using the R 163 
package vegan.[28] Distance based Redundancy Analysis (dbRDA) was used to determine 164 
the cumulative contributions of a matrix of explanatory variables on the response data, 165 
hippurate excretion inter-individual variation (Euclidian distance on log-transformed urine 166 
hippurate concentration matrix) in R package vegan.[28]. Orthogonal partial least squares 167 
discriminant analysis (O-PLS-DA) was performed in MATLAB R2014a for supervised 168 
multivariate analysis as previously described.[29] The predictive capability of O-PLS-DA 169 
models was evaluated through 7-fold cross-validation[29] to compute Q2Yhat goodness-of-170 
prediction parameters. The empirical significance of the Q2Yhat parameter was evaluated by 171 
random permutation testing (10,000 iterations).[30] 172 
Animal experiments 173 
Six-week-old C57BL/6J male mice (Janvier Labs, Courtaboeuf, France) were maintained in 174 
specific pathogen free condition on a 12h light/dark cycle and fed a standard chow diet 175 
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(R04-40, Safe, Augy, France) for a week. Groups of 10 randomly selected mice were then 176 
fed either control chow diet (CHD) (D 12450Ki, Research diets, NJ) or high fat (60% fat and 177 
sucrose) diet (HFD) (D12492i, Research diets, NJ). One week later, osmotic minipumps 178 
(Alzet® model 2006, Charles River Lab France, l’Arbresle, France) filled with a solution of 179 
either hippuric acid or benzoic acid (5.55mM in 0.9% NaCl) (Sigma Aldrich, St Quentin, 180 
France) were inserted subcutaneously under isoflurane anesthesia. The metabolites were 181 
delivered at a rate of 0.15 µL/hour over a 42-day period (20 nmol/day). 182 
Glycemia and body weight were recorded weekly. After 3 weeks of metabolite treatment, 183 
mice underwent an intra-peritoneal glucose tolerance test (IPGTT, 2g/kg). Blood was 184 
collected from the tail vein before glucose injection and 15, 30, 60 and 120 minutes 185 
afterwards to determine glycemia using an Accu-Check® Performa (Roche Diagnostics, 186 
Meylan, France). Cumulative glycemia (AUC) was calculated as the sum of plasma glucose 187 
values during the IPGTT and cumulative glucose increase (ΔG) parameter was calculated 188 
as AUC above the fasting glycemia baseline integrated over the 120 min of the IPGTT. 189 
Insulinemia was determined at baseline and at 30 minutes using insulin ELISA kits 190 
(Mercodia, Uppsala, Sweden). After 6 weeks of metabolite infusion, mice were killed by 191 
decapitation and organs were dissected and weighed. Triglycerides were quantified using a 192 
colorimetric assay (ab65336, Abcam, Paris, France) of liver homogenates. All procedures 193 
were authorized following review by the institutional ethic committee and carried out under 194 
national licence condition (Ref 00486.02). 195 
Histology and immunohistochemistry of animal tissues 196 
Liver fibrogenesis and immunohistochemistry were determined as previously described [31]. 197 
An epitope-specific antibody (C27C9) was used for immunohistochemistry detection of 198 
insulin on pancreas sections (8508S Ozyme, Saint Quentin en Yvelines, France).  199 
RNA isolation and quantitative RT-PCR 200 
Liver RNA preparation and reverse transcription were performed as previously reported [31]. 201 
Quantitative RT-PCRs were performed using oligonucleotides designed for the genes Col1 202 
(Forward: CACCCCAGCGAAGAACTCATA; Reverse: 203 
GCCACCATTGATAGTCTCTCCTAAC) and Col3 (Forward: GCACAGCAGTCCAACGTAGA; 204 
Reverse: TCTCCAAATGGGATCTCTGG) and using the cyclophilin A housekeeping 205 
gene.[31] 206 
  207 
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RESULTS 208 
 209 
Hippurate is the urine metabolite most strongly associated with fecal microbial gene 210 
richness. 211 
To identify microbial and host compounds mediating beneficial effects in metabolic health, 212 
we profiled the urinary metabolome of the MetaHIT population[4] using 1H nuclear magnetic 213 
resonance (NMR) spectroscopy to perform a Metabolome-Wide Association Study 214 
(MWAS)[11] for microbial gene richness, a proposed criterion of metabolic and immune 215 
health[4] (Figure 1). We first built an orthogonal partial least squares (O-PLS) regression 216 
model based on the 1H NMR spectra to stratify the population by gene richness quartiles 217 
computed using our previously published 10-million integrated gene catalog (IGC)[2] (Figure 218 
1A, P=5.8x10-21). The cross-validated model significantly predicted variance associated with 219 
gene richness through a permutation test (Figure 1B, P=9.7x10-5, 10,000 randomizations). 220 
Model coefficients for this discrimination revealed hippurate as having the strongest 221 
association with microbial gene count (Figure 1C): individuals with low microbial richness 222 
present significantly lower urinary hippurate levels than individuals with high microbial 223 
richness (Figure 1D, P=1.99x10-9, r2=0.173). These data support reports of association 224 
between hippurate levels and microbial functional redundancy[26] and Shannon’s diversity 225 
index[17] (Figure1E, P=0.024 and Supplementary Figure 1A, P=0.0058). 226 
 227 
Consistent with associations previously reported for microbial gene richness in the MetaHIT 228 
population[4] and associations between hippurate and reduced cardiometabolic disease 229 
risk[11,12,14,17], urinary hippurate significantly correlated with low values for body mass 230 
index (BMI), bodyweight, the homeostasis model assessment of insulin resistance (HOMA-231 
IR) and fasting circulating levels of IL6, insulin, and C-peptide, whilst adjusting for age and 232 
gender (partial Spearman’s rank-based correlations, q<0.1, Supplementary Figure 1B). 233 
Moreover, stratification on urinary hippurate concentrations in lean (BMI <25 kg/m2), and 234 
overweight or obese (BMI >25 kg/m2) individuals showed improved glucose homeostasis in 235 
participants excreting higher levels of hippurate (Supplementary Figure 1C, median 236 
threshold). These observations depict hippurate, one of the main microbial-mammalian co-237 
metabolites found in human urine, as a key molecular marker associated with gene richness 238 
which may underlie some of its health benefits. These results however raise questions 239 
related to the entanglement of gene richness and hippurate as potential markers of 240 
health[13,17]. Adjusting for hippurate weakens associations between gene richness and 241 
bioclinical variables (Supplementary Figure1B), consistent with the idea that hippurate could 242 
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mediate some of the observed benefits for subjects with higher gene richness. However, 243 
hippurate associations with bioclinical variables adjusted for gene richness are no longer 244 
significant, suggesting that the gene richness signal overrides hippurate associations in the 245 
presence of confounding variation affecting urinary concentrations, such as diet, microbial 246 
synthesis, host conjugation and clearance. Hippurate did not correlate either to glycine 247 
bioavailability, which is required for hippurate synthesis through conjugation with gut 248 
microbial benzoate[32] or kidney function (eGFR) which could limit hippurate synthesis and 249 
clearance (Supplementary Figure 1D-E). 250 
 251 
Microbiome determinants of hippurate production in the phenylpropanoid pathway 252 
To characterize the microbial determinants of benzoate production, we next focussed on 253 
high-throughput shotgun sequencing fecal metagenomics data (n=271). We functionally 254 
annotated functions of the IGC to KEGG Orthology (KO) groups and found 2,733 KEGG and 255 
6,931 EggNOG modules positively associated with urine hippurate levels (pFDR<0.05, 256 
Supplementary Tables S1-2). Of specifically curated enzymatic modules[26] involved in 257 
microbial benzoate metabolism (4 aerobic and 15 anaerobic; Supplementary List), only three 258 
modules significantly correlated with urine hippurate levels: MC0004 (detected in 271 259 
samples) corresponding to a 2-enoate reductase converting cinnamic acid into 3-(3-260 
hydroxyphenyl)-propionic acid, MC0005 (observed in 201 samples) converting cinnamate 261 
into benzoate and MC0014, a benzoate 4-monooxygenase only observed in fewer than 15% 262 
of individuals (Figure 2A, Supplementary Table S3). Abundance of these modules also 263 
correlated with gene richness (Supplementary Table S4), thereby providing a functional 264 
basis for the association between gene richness and urine hippurate levels observed in this 265 
population (Figure 1). Genes involved in MC0004 and MC0005 were predominantly found in 266 
genomes from unclassified Firmicutes and Clostridiales (Figure 2B, Supplementary Tables 267 
S5-6). Among classified Firmicutes, the genera Lachnoclostridium, Eubacterium and Blautia 268 
harbored MC0004. Conversely, MC0005 was encoded by Proteobacteria, i.e. Klebsiella, 269 
Enterobacter, Suterella and Comamonas (Figure 2B). We then mapped these modules into 270 
the enteroscape (as observed on the principal coordinates plot derived from normalized 271 
genus abundances using Bray-Curtis distances,[26] Figure 2C), revealing that the 272 
conversion of cinnamic acid into 3-hydroxy-3-phenylpropionic acid is linked to the 273 
Ruminococcus enterotype, while capacity to convert cinnamate to benzoate is more 274 
ubiquitously distributed across gut community types. Phenylpropanoid pathway potential is 275 
increased in the Ruminococcaceae-enterotype compared to the Bacteroides- or Prevotella-276 
enterotypes, the former being confirmed by analyzing gradients of key taxa instead of 277 
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enterotypes (Supplementary Table S7). The results altogether suggest a wide range of 278 
substrates, taxa and species are involved in benzoate production, consistent with its 279 
association with gene richness. 280 
 281 
Urine hippurate levels associate with improved metabolic health in patients with diets 282 
rich in meat and saturated fats 283 
We next assessed individual nutritional intake through validated FFQs available in 193 284 
MetaHIT individuals.[19] Associations with metabolic health were stratified according to 285 
multivariate dietary patterns (Figure 3). A PCA of 133 dietary intake descriptors summarises 286 
dietary patterns and loadings highlight four archetypal diets within our population: higher 287 
consumption of fruits and vegetables (n=96) vs. high consumption of meat containing 288 
saturated fats (n=97) on the first principal component (PC1) and carbohydrate-rich foods vs. 289 
fish containing unsaturated fats on PC2 (Figure 3A), a trend which was observed at the food 290 
ingredient and nutrient level (Supplementary Figure 2A-B). It is therefore possible to stratify 291 
the population according to the median of dietary PC1 highlighting contrasts between 292 
healthy (higher consumption of fruit and vegetables) and at-risk (higher consumption of 293 
carbohydrates and meat) diets. Although hippurate was not correlated with the first two 294 
dietary principal components, its dynamic range was similar whilst stratifiying according to 295 
the first two principal components (Supplementary Figure 2C-E). To summarise the main 296 
factors influencing inter-individual variation in urine hippurate excretion, we calculated the 297 
cumulative contribution of several covariates using a dbRDA ordination approach (Figure 298 
3B). Gene richness accounted for 12% (P=0.002), followed by MC0020 encoding a 299 
hippurate dehydrolase (4%, P=0.002, observed in 271 subjects) catalysing the 300 
retroconversion of hippurate into benzoate, and HOMA-IR (1.5%, P=0.008; n=265). When 301 
taking diet into account (i.e., PC1 fruits and vegetables vs. meat; n=193) in the dbRDA, gene 302 
richness contributes to 15% (P=0.002), diet adding another 4% (P=0.002) and hippurate 303 
retroconversion 3% (P=0.004), suggesting that the pattern of hippurate associations could 304 
be diet-dependent and requiring further analysis. We therefore stratified the data according 305 
to diet (n=193) using a median threshold for the first dietary principal component, 306 
highlighting a healthy diet associated with vegetables and fruit intake (low PC1 values, n=96) 307 
and an at-risk diet rich in saturated fats derived from meat intake (n=97). For this latter 308 
subset of individuals consuming a diet rich in saturated fats on the first dietary principal 309 
component, urine hippurate levels significantly associated with decreased HOMA-IR, 310 
circulating fasting levels of insulin, fasting associated adipocyte factor (FIAF, also known as 311 
Angiopoietin-like 4, a peroxisome proliferator-activated receptor target gene environmentally 312 
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modulated by the gut microbiota inhibiting lipoprotein lipase in adipose tissue [33]) and TNF-313 
a, whilst displaying increased plasma levels of fasting adiponectin (Figure 3C-E, 314 
Supplementary Table S8). Urine hippurate was not associated with any health benefits in the 315 
subsets of participants consuming mostly a fruit and vegetable diet, a pescetarian diet or a 316 
carbohydrate-rich diet (Supplementary Table S8). 317 
 318 
To disentangle contributions arising from hippurate and gene richness to bioclinical variables 319 
in subjects consuming a diet rich in fats, we compared unadjusted and adjusted Spearman’s 320 
rank-based correlations (Figure 3H). In the population consuming higher amounts of meat 321 
and saturated fats, elevated urine hippurate levels significantly associated with an increase 322 
in fasting plasma adiponectin and a reduction in adiposity, BMI, HOMA-IR and fasting 323 
plasma insulin, which is consistent with gene richness being significantly associated with an 324 
increase in adiponectin and a decrease in HOMA-IR and fasting plasma insulin. However, 325 
the associations between gene richness and bioclinical variables were no longer significant 326 
when adjusting for urine hippurate levels. Conversely, hippurate associations with insulin 327 
and HOMA-IR were still significant after gene richness adjustment. We exemplified this 328 
through a correlation graph taking into account the correlation between hippurate and gene 329 
richness (r=0.44): this unadjusted correlation between gene richness and HOMA-IR 330 
collapses when adjusting for gene richness (rho=0.143, n.s.) and is in fact contributed for by 331 
a partial correlation between urine hippurate and HOMA-IR (Figure 3I). The latter finding 332 
suggests a possible preventive role for hippurate in metabolic disease driven by diets high in 333 
meat and saturated fats, independently of gene richness. 334 
 335 
Hippurate and benzoate improve glucose tolerance in HFD-fed mice 336 
To further study the impact of benzoate and hippurate on host physiology, we treated mice 337 
with subcutaneous infusion of hippurate (0.14 mg/kg/day) and benzoate (0.1 mg/kg/day) in 338 
CHD and HFD (Figure 4). Under control diet, metabolite treatments had no effect on body 339 
weight, BMI and fasting glycemia (Supplementary Figure 4). Benzoate caused a significant 340 
elevation of the adiposity index and a reduction of the normalised heart weight 341 
(Supplementary Figure 5A). During an IPGTT, both metabolites induced a slight increase in 342 
glycemia (Figure 4A-B) and ΔG parameter (Figure 4C), respectively. Also, hippurate induced 343 
a stronger glucose-stimulated insulin secretion than benzoate, compared to the saline-344 
treated mice (Figure 4D). Whilst HFD-feeding increased body weight and adiposity, 345 
hyperglycemia and glucose intolerance (Figure 4E-H, Supplementary Figs 4D,E and 5), 346 
mice treated with hippurate or benzoate showed a parallel improvement in glucose tolerance 347 
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compared to saline-treated controls (Figure 4E). This effect was illustrated by the highly 348 
significant reduction of both the cumulative glycemia during the test (Hippurate vs. control -349 
23.90% P=0,001, benzoate vs. ctl -31.52%, P=0.001) and the ΔG parameter (Hippurate vs. 350 
ctrl -37.22% P=0,001, benzoate vs ctrl -33.35%, P=0.001) (Figure 4F,G). Hippurate and 351 
benzoate treatments also significantly increased glucose-induced insulin secretion (Figure 352 
4H). These data suggest that both metabolites have the capacity to improve glucose 353 
tolerance and stimulate glucose-induced insulin secretion in vivo specifically in diet-induced 354 
obesity and diabetes. 355 
 356 
Effects of hippurate and benzoate on the morphology of pancreatic islets  357 
To investigate the possible cause of stimulated insulin secretion by hippurate and benzoate, 358 
we performed out a histological analysis of pancreatic islet structure. We confirmed that 359 
insulin positive area was increased by hippurate (+194%, P=0.04, one-tailed) or benzoate 360 
(+437%, p=0.02, one-tailed) respectively in mice fed control diet (Figure 5); hippurate 361 
treatment Insulin positive area was also increased in HFD-fed mice treated with hippurate 362 
(+168%, P=0.04, one-tailed). These data suggest that increased β-cell mass may explain 363 
enhanced insulin production and secretion induced by hippurate and benzoate treatment. 364 
 365 
Effects of hippurate and benzoate on liver histopathology and function 366 
Liver triglyceride accumulation, fibrosis and inflammation are hallmarks of structural and 367 
biochemical adaptations to HFD feeding. Liver triglycerides were more elevated in HFD fed 368 
mice (29.30±4.15 mg/g) than in mice fed control diet (8.63±2.19 mg/g, P=0.002) 369 
(Supplementary Figure 6). Hepatic triglycerides were not significantly affected by hippurate 370 
or benzoate treatment in either diets. Benzoate induced a singifnicant decrease in liver 371 
triglycerides compared to hippurate in HFD (-57.35%, P= 0.02) (Supplementary Figure 6). 372 
We next analysed hepatic fibrosis through quantitative analysis of collagen detected by red 373 
picrosirius staining of histological sections (Figure 6A). Hippurate treatment resulted in a 374 
marked reduction of liver collagen in mice fed control diet (-53.2%) or HFD (-55.7%), 375 
whereas benzoate had no effects on collagen levels in these mice (Figure 6B,C). These 376 
results were confirmed by liver expression of the genes encoding collagen 1 (Col1) and 377 
collagen 3 (Col3) (Figure 6B,C): hippurate treatment induced a significant reduction of the 378 
expression of Col1 (-79.89%, P=0.02) and Col3 (-29.37%, P=0.01) under control diet (Figure 379 
6B). but the effect of the metaolites on Col1 and Col3 I HFD was marginal (Figure 6C). 380 
Finally, we assessed the effects of hippurate and benzoate on liver inflammation through a-381 
SMA (alpha Smooth Muscle Actin) staining[34,35] (Figure 7A), which is increased by HFD-382 
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
perpetuity.
this preprint (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in 
The copyright holder for. http://dx.doi.org/10.1101/2019.12.15.876672doi: bioRxiv preprint first posted online Dec. 16, 2019; 
 13 
feeding (+273.86%) (Figure 7B,C). Hippurate induced a marked reduction in a-SMA staining 383 
in mice fed control diet (-82.71%) or HFD (-94.87%) (Figure 7B,C), suggesting reduced 384 
presence of stellar cells and reduced liver inflammation when compared to saline-treated 385 
controls. In contrast, benzoate treatment in chow diet induced a strongly significant increase 386 
in stellar cells when compared to mice treated with saline (+564%, P=10-7) or hippurate 387 
(+3,741%, P=10-7), thereby indicating liver inflammation in these mice (Figure 7B). 388 
Collectively, these data show that hippurate decreases fibrosis and inflammation regardless 389 
of diet, whereas benzoate reduces triglycerides and collagen accumulation in obese mice 390 
fed HFD whilst stimulating inflammation in lean mice fed control diet. 391 
 392 
DISCUSSION 393 
 394 
Integrated analysis of metabolome profiling and deep metagenome sequencing data of 271 395 
middle-aged non-diabetic Danish subjects from the MetaHIT study sample [4] identified 396 
urinary hippurate as the metabolite most significantly associated with microbial gene 397 
richness based on the microbial IGC.[2] This observation largely confirms previous reports 398 
associating hippurate with gene richness in steatosis and bariatric surgery contexts[14,36] 399 
as well as with increased gut microbial diversity as assessed by sequencing the 16S rRNA 400 
gene amplicon.[17] Hippurate having previously been inversely correated with blood 401 
pressure, obesity and steatosis,[11-14] this study highlights diet-dependent relationships 402 
between microbiota-host co-metabolism of benzoate and hippurate and health benefits 403 
associated with gene richness. Our in-depth dissection of the metagenomic determinants of 404 
urinary hippurate highlighted a series of richness-responsive gene modules functionally 405 
related to benzoate synthesis. These modules are shared across several enterotypes and 406 
taxonomic gradients. Population stratification analyses demonstrated that hippurate only 407 
benefits individuals consuming a diet rich in saturated fats. This hypothesis of a diet-408 
dependent beneficial health effect of benzoate metabolism was confirmed in vivo in a 409 
preclinical model of HFD-induced obesity. 410 
 411 
Hippurate brings diet-dependent metabolic improvements in pancreas and liver 412 
Our study shows that chronic hippurate treatment in a model of obesity induced by HFD-413 
feeding reduces glucose intolerance, stimulates insulin secretion, enhances β-cell mass and 414 
reduces hepatic inflammation and fibrosis. Metabolomic studies have consistently shown 415 
inverse associations variations between hippurate levels and pathophysiological elements of 416 
the metabolic syndrome. Urinary hippurate is reduced in mouse models of insulin 417 
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resistance[10] and in rat models of spontaneously occurring hypertension (SHR), type 2 418 
diabetes (Goto Kakizaki, GK) and obesity (Zucker) or the WKY rat.[37-39] This is consistent 419 
with our previous reports showing an inverse association among hippurate, insulin 420 
resistance, hypertension, obesity or liver steatosis[10-12,14] and observations that hippurate 421 
exerts protective effects in β-cells.[40] We also showed in HFD-fed isogenic mice that 422 
urinary hippurate measured before a 3-week HFD induction predicts the future development 423 
of obesity, suggesting that functional variations in microbiome predicts disease risk 424 
independently of genetics.[41] Whilst both hippurate and benzoate have similar in vivo 425 
effects, including greatly improved glucose tolerance and stimulation of insulin secretion, 426 
only hippurate results in beneficial effects on increased β-cell mass or reduced liver fibrosis.  427 
 428 
The phenylpropanoid-benzoate-hippurate pathway in metabolic health 429 
The range of responses observed in the animal model treated with hippurate and benzoate 430 
depict subtle and context-dependent microbiome–host interactions. Benzoate and its co-431 
metabolite hippurate are the endproducts of several converging microbial biosynthetic 432 
pathways.[15] The phenylpropanoid pathway is a broad network of reactions connecting a 433 
wide range of dietary substrates such as phenylalanine, quinic acid, shikimic acid or 434 
chlorogenic acid for instance to 4-coumaryl-coA. These pathways lead to much simpler 435 
molecules, benzoate being their common endpoint. Dietary and microbial intermediates 436 
(including cinnamic acids, coumarins, stillbenoids, flavonoids and isoflavonoids) in the 437 
phenylpropanoid and connected pathways are associated with beneficial health 438 
outcomes.[15,42] 439 
 440 
Conclusion. Our study depicts hippurate as a pivotal microbial-host co-metabolite mediating 441 
part of the beneficial metabolic improvements associated with high microbial gene richness 442 
in the context of Western-style diets. This work unifies previous reports in which hippurate 443 
was associated improvements in insulin resistance, steatosis, hypertension and obesity[10-444 
12,14] and microbial ecological diversity.[14,17] Beyond the diversity of microbial 445 
ecosystems and functions associated with hippurate, we uncover beneficial bioactivities in 446 
the liver and pancreas resulting in health benefits in terms of metabolic control, liver 447 
inflammation and fibrosis. Our observations support the existence of diet-dependent 448 
microbial-host metabolic axis in which hippurate partly offsets unhealthy diets, further 449 
exemplifying that the microbiome determines key components of human biochemical 450 
individuality[43] and provides critical diagnostic and therapeutic potential in personalized 451 
nutrition and stratified medicine.[44,45]   452 
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Figure Legends 474 
 475 
Figure 1. Hippurate is the main metabolite correlated with gene richness and 476 
functional redundancy of the microbiome. (A) Scores plot (predictive component 1) 477 
obtained for an O-PLS-DA model fitted usingurinary1H NMR-spectra to predict microbial 478 
gene richness, showing a significant association between gene richness quartiles and 1H 479 
NMR spectra (p=5.84x10-21 for a significantly non-zero slope using F-test, n=271). (B) 480 
Empirical assessment of the significance of O-PLS goodness-of-fit parameter Q2Yhat by 481 
generating a null distribution with 10,000 random permutations (p=9.68x10-5). (C) Manhattan 482 
plot highlighting associations between 1H NMR variables and gene count displayed in a 483 
pseudo-spectrum layout. A negative value (blue circles) means a negative correlation while 484 
a positive value (red circles) means a positive correlation. Grey circles are clusters with a p-485 
value>0.01. Size of circles represents the covariance of the cluster with the gene count.( D) 486 
Association between urinary hippurate intensity and gene count quartiles (p=1.99x10-9 for a 487 
significantly non-zero slope using F-test). (E) Association between urinary hippurate intensity 488 
and microbial functional redundancy [26] quartiles (p=0.0239 for a significantly non-zero 489 
slope using F-test, n=271). 490 
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 491 
Figure 2. Detection of microbial phenylpropanoid metabolism-related modules in fecal 492 
metagenomes of healthy volunteers and their associations with urine hippurate 493 
concentrations. (A) Visualisation of gut-specific metabolic modules (GMMs) encoding 494 
anaerobic phenylpropanoid metabolism-related pathways detected in more than 20% of 495 
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individuals; MC0004 (orange; Spearman rho=0.19, q-value=0.005) and MC0005 (blue; 496 
Spearman rho=0.21, q-value=0.005) correlate positively to urine hippurate concentrations 497 
(n=271). All metabolites are connected to benzoate but for clarity the non-significant 498 
reactions were omitted. (B) Metagenomic species encoding modules MC0004 and MC0005. 499 
(C) [top panel] Fecal microbiomes dissimilarity visualised on the first plane of the genus-level 500 
principal coordinates analysis (PCoA, Bray-Curtis dissimilarity), with individual samples 501 
colored according to enterotypes (R, Ruminococcaceae; B, Bacteroides; P, Prevotella). 502 
[middle and bottom panels] Same genus-level PCoA overlaid with a mesh colored according 503 
to the median abundances of GMMs MC0004 (red) and MC0005 (blue) in samples falling 504 
within each cell of the mesh (n=271).  See Supplementary Table S3 for correlation between 505 
hippurate and GMMs. 506 
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 507 
Figure 3. Hippurate associates with improved glucose homeostasis only in 508 
participants consuming a diet rich in saturated fats. (A) Biplot of the principal 509 
component analysis (PCA) of dietary intakes highlights opposite diets along first two 510 
principal components (PCs). The main drivers of each principal components are named and 511 
represented by blue arrows. (B) Cumulative contributions of explanatory variables to inter-512 
individual variation in hippurate excretion, estimated by redundancy analysis (dbRDA). 513 
Explanatory variables included microbiota gene count, microbiota phenylpropanoid 514 
metabolism modules, host dietary principal components and clinical parameters (age, 515 
gender, BMI, HOMA-IR, CRP, serum glycine levels, and glomerular filtration rate (eGFR) 516 
estimation with CKD-EPI). (C-F) Evaluation of hippurate stratification (high hippurate, n=49 517 
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vs low hippurate, n=48) on bioclinical variables (q<0.1, Supplementary Table S8) for 518 
individuals on high PC1 (i.e. high meat / high saturated fat diet). For full name description of 519 
physiological data see Supplementary Table S8. 520 
  521 
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 522 
 523 
Figure 4. Chronic hippurate treatment improves glucose homeostasis in HFD-fed 524 
mice.  525 
(A) Heatmap summarising Spearman’s partial correlation between gene richness, 526 
hippurate,gene richness adjusted for hippurateand hippurate adjusted for gene richness and 527 
bioclinical variables, all correlations adjusted for age and gender. Stars represent significant 528 
pFDR corrected using Benjamini Hochberg procedure * pFDR<0.1, ** pFDR<0.05, *** 529 
p<0.01. (B) Representation of the Spearman’s correlations and partial correlations between 530 
gene count and hippurate, hippurate and HOMA-IR adjusted for gene richness and between 531 
gene richness and HOMA-IR adjusted for hippurate. (C) Plasma glucose during a glucose 532 
tolerance test (GTT). (D) Area under the curve for glucose during the GTT. (E) Body weight 533 
of mice during the 6 weeks of hippurate treatment. (F) Body mass index at sacrifice (G) 534 
Adipose tissue weight normalised to body weight. (H) Plasma adiponectin concentration. For 535 
chow diet and chow diet + hippurate, (n=10) and for HFD and HFD + hippurate (n=6). Data 536 
shown are mean±SEM. Statistical analysis was performed using two-way ANOVA with 537 
Tukey’s posthoc test. ** p<0.01, **** p<0.0001. For panel (D), (F), (G) and (H), groups with 538 
different superscript letters are significantly different (P<0.05), according to Tukey’s posthoc 539 
test. 540 
 541 
 542 
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 543 
Figure 5. Effect of chronic administration of hippurate and benzoate on pancreatic 544 
islets in C57BL6/J mice. The effect of chronic subcutaneous administration of the 545 
metabolites (5.55 mM) for 42 days on islet density was tested in mice fed chow diet (CHD) 546 
or high fat diet (HFD) for 56 days. Control mice were treated with saline. Each biological 547 
replicate represents one slide per animal mounted with at least 3 tissue sections, 548 
representing 3 technical replicates, the mean and variance of which is presented as the 549 
result per biological replicate. Results are expressed as percentage of positive pixels. 550 
‡P<0.05, significantly different between mice treated with benzoate and hippurate. 551 
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 552 
Figure 6. Effect of chronic administration of hippurate and benzoate on liver fibrosis 553 
in C57BL6/J mice. (A)The effect of chronic subcutaneous administration of the metabolites 554 
(5.55 mM) for 42 days on liver collagen was tested in mice fed control chow diet (CHD) or 555 
high fat diet (HFD) for 56 days. Control mice were treated with saline. Red Picrosirius 556 
staining of histological sections was used to visualise and quantify fibrosis in mice fed CHD 557 
(B) or HFD (C). Each biological replicate represents one slide per animal mounted with at 558 
least 3 tissue sections, representing 3 technical replicates, the mean and variance of which 559 
is presented as the result per biological replicate (B,C). Liver expression of the genes 560 
encoding collagen 1 (Col1) and collagen 3 (Col3) was assessed in mice fed CHD (B) or HFD 561 
(C) by quantitative RT PCR in 6 mice per group. Data were analyzed using the unpaired 562 
Mann-Whitney test. Results are means ± SEM. *P<0.05 significantly different between mice 563 
treated with hippurate and controls. ‡P<0.05, significantly different between mice treated 564 
with benzoate and hippurate. 565 
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 566 
Figure 7. Effect of chronic administration of hippurate and benzoate on liver 567 
inflammation in C57BL6/J mice. αSMA staining of liver slides was used to assess 568 
inflammation in mice fed chow diet (CHD) or high fat diet (HFD) for 56 days and chronically 569 
treated with subcutaneous administration of the metabolites (5.55mM) for 42 days (A). 570 
Control mice were treated with saline. Each biological replicate represents one slide per 571 
animal mounted with at least 3 tissue sections, representing 3 technical replicates, the mean 572 
and variance of which is presented as the result per biological replicate in mice fed CHD (B) 573 
or HFD (C). Data were analyzed using the unpaired Mann-Whitney test. Results are means 574 
± SEM.  575 
††††P<0.0001, significantly different between mice treated with benzoate and saline treated 576 
controls. ‡‡‡‡P<0.0001, significantly different between mice treated with benzoate and 577 
hippurate. 578 
579 
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SUPPLEMENTARY SECTION 580 
 581 
 582 
Supplementary Figure 1. Relationship between gene richness, hippurate and 583 
bioclinical variables 584 
(A) Association between urinary hippurate intensity and Shannon’s diversity index quartiles 585 
(p=6.04x10-8for a significantly non-zero slope using F-test, n=271). (B) Heatmap 586 
summarising significant (pFDR<0.1) Spearman’s correlation FDR corrected using Storey’s 587 
procedure[27] betweengene count, hippurate and gene count adjusted for hippurate and 588 
physiological data, all adjusted for age and gender.For full physiological data names and 589 
units see Supplementary Table 8. (C) Association between hippurate and insulin resistance 590 
(HOMA-IR) stratified according to BMI (lean (BMI≤25, n=87), overweight and obese (BMI>25 591 
,n=184) and hippurate excretion levels (Mann-Whitney U test, p=0.0058). (D) 592 
Representation of the absence of significant correlation between urinary hippurate and 593 
eGFR. (E) Representation of the absence of significant correlation between urinary 594 
hippurate and circulating glycine. 595 
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 596 
Supplementary Figure 2. Urinary hippurate does not correlate with main dietary 597 
trends summarized and presents a high variability within each subgroup 598 
(A) Biplot of the dietary data generated using only food items. (B) Biplot of thmicrobial e 599 
dietary data generated using only macronutrients items. (C) Representation of the absence 600 
of correlation between hippurate concentration and principal component 1. (D) 601 
Representation of the absence of correlation between hippurate concentration and principal 602 
component 2. (E) Distribution of hippurate urinary concentration within each 603 
individualsubgroup stratified in high and low hippurate using median. 604 
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 605 
Supplementary Figure 3. Experimental design for chronic six-week administration of 606 
benzoate and hippurate  607 
Experiment design showing groups and durations of each step for the chronic treatments 608 
with benzoate and hippurate in mice. 609 
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 611 
 612 
Supplementary Figure 4. Effects of chronic administration of hippurate and benzoate 613 
on body growth and fasting glycemia. C57BL6/J mice fed control chow diet (A-C) or high 614 
fat diet (D-F). The effects of chronic subcutaneous administration of the metabolites (5.55 615 
mM) in mice were tested on body weight (A,D), body mass index (BMI) (B,E), fasting 616 
glycemia (C,F). Control mice were treated with saline. BMI was calculated as body weight 617 
divided by the squared of anal-nasal length. Results are means ± SEM.  618 
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 619 
Supplementary Figure 5. Organ weight in C57BL6/J mice treated chronically with hippurate 620 
or benzoate for 42 days. Control mice were treated with saline. Mice were fed chow diet 621 
(CHD) or high fat diet (HFD) for 56 days. Data are expressed as the ratio between organ 622 
weight and body weight. Data were analyzed using the unpaired Mann-Whitney test. Results 623 
are means ±SEM. 624 
**P<0.01, significantly different between mice treated with hippurate and controls. †P< 0.05, 625 
††P<0.01, significantly different between mice treated with benzoate and saline treated 626 
controls.  627 
  628 
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 629 
 630 
Supplementary Figure 6. Effect of chronic administration of hippurate and benzoate 631 
on liver triglycerides content in C57BL6/J mice. The effect of chronic subcutaneous 632 
administration of the metabolites (5.55mM) for 42 days on liver triglycerides was tested in 633 
mice fed control chow diet (CHD) or high fat diet (HFD) for 56 days. Assay was carried out in 634 
6 mice per group. Data were analyzed using the unpaired Mann-Whitney test. 635 
Results are means ± SEM  636 
‡P<0.05, significantly different between mice treated with benzoate and hippurate. 637 
 638 
  639 
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Supplementary Table S1 640 
Association between microbiota functional potential mapped to KEGG Orthologs (KOs) 641 
database and urine hippurate levels. 642 
 643 
Supplementary Table S2 644 
Association between microbiota functional potential mapped to the eggNOG database and 645 
urine hippurate levels. 646 
 647 
Supplementary Table S3 648 
Association between microbiota functional potential mapped to gut-specific metabolic 649 
modules (GMMs) describing phenylpropanoid metabolism and urine hippurate levels. 650 
 651 
Supplementary Table S4 652 
Association between abundance of gut-specific metabolic modules (GMMs) describing 653 
phenylpropanoid metabolism and gene richness. 654 
 655 
Supplementary Table S5 656 
Phenylpropanoid metabolism potential in metagenomic species, assessed by mapping to 657 
GMMs significantly associated to urine hippurate levels. 658 
 659 
Supplementary Table S6 660 
Association between the microbiota composition profiled as metagenomic OTUs (mOTUs) 661 
and urine hippurate levels. 662 
 663 
Supplementary Table S7 664 
pFDR from Spearman’s rank-based correlations between GMMs describing 665 
phenylpropanoid metabolism and gene richnessbioclinical variables using Storey’s FDR 666 
correction. 667 
 668 
Supplementary Table 8 669 
pFDR from Mann-Whitney U test for hippurate stratification in each bioclinical variable 670 
between using Storey’s FDR correction. 671 
 672 
  673 
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Supplementary List: Module definitions 
 
MC0001 phenylalanine degradation (cinnamate production) 
cpd [phenylalanine] [cinnamate, NH3] 
K10775 
ref MetaCyc Pathway: trans-cinnamoyl-CoA biosynthesis 
 
MC0002 chlorogenate degradation 
cpd [chlorogenate] [caffeate, quinate] 
K06889 K09252 
ref MetaCyc Pathway: chlorogenic acid degradation 1 
 
MC0003 caffeate respiration 
cpd [caffeate] [hydrocaffeate] 
bactNOG04579 
ref 2 
 
MC0004 cinnamate conversion 
cpd [cinnamate] [3-(3-hydroxyphenyl)propanoate] 
K10797 
ref KEGG Pathway: phenylalanine degradation 
 
MC0005 coumarate degradation 
cpd [coumarate] [hydroxybenzoate] 
cpd [ferulate] [vanillate] 
cpd [caffeate] [protocatechuate] 
cpd [cinnamate] [benzoate] 
K01904 bactNOG05057 
K01692 K01715 K01782 K01825 K13767 K15016 bactNOG19280 
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K00141 
ref MetaCyc Pathway: 4-coumarate degradation (anaerobic) 3 
 
MC0006 (hydroxy)benzoate degradation 
cpd [(hydroxy)benzoate] [3-hydroxypimeloyl-CoA] 
K04105,K04107,K04108,K04109 K04110 bactNOG00950 
K04112,K04113,K04114,K04115 K19515,K19516 
K07537 
K07538 
K07539 
ref MetaCyc Pathway: 4-coumarate degradation (anaerobic) MetaCyc Pathway: benzoyl-CoA 
degradation II (anaerobic) Kegg module: M00541 
 
MC0007 ferulate degradation 
cpd [ferulate] [vanillin] 
K12508 
K18383 
ref MetaCyc Pathway: ferulate degradation 
 
MC0008 vanillate conversion 
cpd [vanillin, (O2)] [protocatechuate] 
bactNOG00059 
K03862,K03863 K15066 
ref MetaCyc Pathway: superpathway of vanillin and vanillate degradation Kegg Pathway: 
aminobenzoate degradation  
 
MC0009 cinnamate degradation 
cpd [cinnamate] [benzoyl-CoA] 
bactNOG08521 
actNOG07134 
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COG0277 
bactNOG05297 
ref MetaCyc Pathway: trans-cinnamoyl-CoA biosynthesis MetaCyc Pathway: benzoyl-CoA 
biosynthesis 
 
MC0010 quinate degradation 
cpd [quinate] [protocatechuate] 
cpd [shikimate] [protocatechuate] 
K05358 COG0169 
K03785 K03786 K13832 
K09483 K15652 
ref MetaCyc Pathway: quinate degradation I MetaCyc Pathway: quinate degradation II
 4 
 
MC0011 4-hydroxybenzoate conversion 
cpd [4-hydroxybenzoate, O2] [protocatechuate] 
K00481 
ref Kegg Pathway: benzoate degradation 4 5 
 
MC0012 catechin degradation 
cpd [catechin] [protocatechuate, phloroglucinol carboxylic acid] 
bactNOG14887 
ref 6 
 
MC0013 3-hydroxybenzoate conversion 
cpd [3-hydroxybenzoate, O2] [protocatechuate] 
K19065 
ref Kegg Pathway: benzoate degradation 
 
MC0014 benzoate conversion 
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cpd [benzoate, O2] [4-hydroxybenzoate] 
K07824 
ref Kegg Pathway: benzoate degradation 
 
MC0015 benzoate degradation (aerobic) 
cpd [benzoate, O2] [catechol, CO2] 
K05549,K05550,K05784 
K05783 
ref Kegg module: M00551 MetaCyc Pathway: benzoate degradation I (aerobic) 
 
MC0016 benzoate degradation (anaerobic) 
cpd [benzoyl-CoA] [3-hydroxypimeloyl-CoA] 
K04112,K04113,K04114,K04115 K19515,K19516 
K19066 
K07534 
K07535 
K07536 
K04118 
ref MetaCyc Pathway: benzoyl-CoA degradation III (anaerobic) Kegg module: M00540 
 
MC0017 phenylalanine degradation 
cpd [phenylalanine, 2-oxoglutarate] [CO2, glutamate, benzoyl-CoA] 
K00832 K00812 K00813 K11358 K00817 
K04103 
K00146 K00129 
K01912 
K18361 
K18355,K18356,K18357,K18358,K18359 
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ref MetaCyc Pathway: phenylacetate degradation II (anaerobic) MetaCyc Pathway: L-
phenylalanine degradation II (anaerobic) 
 
MC0018 cellulose and hemicellulose degradation (cellulolosome) 
cpd [cellulose, hemicellulose] [ferulate, polysaccharide, oligosaccharide] 
K01181 K13465 
K09252 
bactNOG05428 
ref MetaCyc Pathway: cellulose and hemicellulose degradation (cellulolosome) 
 
MC0019 feruloyl esterase (cellulolosome) 
cpd [cellulose, hemicellulose] [ferulate] 
K09252 
ref MetaCyc Pathway: cellulose and hemicellulose degradation (cellulolosome) MC0018 
 
MC0020 hippurate hydrolase 
cpd [hippurate] [glycine, benzoate] 
K01451 
ref 7 
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